Description
Developer of vascular products designed to address vascular deficiencies. The company specializes in stem cell research and human allograft tissue deployment services, providing researchers and physicians with products useful in biological vascular tissue implantation.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Later Stage VC (Series C) | 10-Mar-2023 | $4.11M | 000.00 | 000.00 | Completed | Generating Revenue |
2. Early Stage VC | 12-Sep-2018 | 00.000 | 00.000 | 000.00 | Completed | Generating Revenue |
1. Early Stage VC (Series A) | 28-Aug-2014 | $2.01M | $2.01M | 00.000 | Completed | Startup |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series C | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.00 | |
Series B | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
Series A | 3,445,076 | $0.001000 | $1.15 | $1.15 | 1x | $1.15 | 24.96% |
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-3086408-A1 | Compositions and methods for treating nerve injury | Pending | 08-Jan-2018 | 000000000 | |
AU-2019205822-A1 | Compositions and methods for treating nerve injury | Inactive | 08-Jan-2018 | 000000000 | |
EP-3737355-A1 | Compositions and methods for treating nerve injury | Inactive | 08-Jan-2018 | 000000000 | |
US-20200353008-A1 | Compositions and methods for treating nerve injury | Pending | 08-Jan-2018 | 000000000 | |
EP-3737355-A4 | Compositions and methods for treating nerve injury | Inactive | 08-Jan-2018 | A61K9/0014 | 0 |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Glen Gong | President, Chief Executive Officer & Board Member | ||
Dale Peterson Ph.D | Chief Technology Officer & Board Member |
Name | Representing | Role | Since |
---|---|---|---|
Dale Peterson Ph.D | MicroVascular Tissues | Chief Technology Officer & Board Member | 000 0000 |
Kevin Oshasi | Self | Board Member | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Pond Capital | Venture Capital | Minority | 000 0000 | 000000 0 |